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Over the past two decades, bone tissue engineering has been the issue of considerable research in the era of regenerative medicine. The reason might be attributed to the many skeletal problems stay undertreated, which leads to rigorous optimization and improvement of regeneration therapies. The current trends include the technical advances in orthopedic implants and surgical techniques for bone regeneration. In the plethora of treatments available for bone reconstruction, gene therapy has also gain significant attention. For bone regeneration, tissue engineering strategies comprise protein, gene, and cell delivery to the defective bone site. Furthermore, the bone repair process was significantly enhanced by biomimetic scaffolds and scaffolds loaded with bone anabolic agents. Directed and controlled gene therapy at defective bone region has the major prospective of augmenting bone defect healing through local delivery of osteogenic genes to lesion in bones, thus circuitously declining systemic toxicity and necessity to use elevated dosages of therapeutic proteins. Gene-activated matrices (GAMs) have shown considerable outcomes with bone regeneration. In GAM technology, cytokines and growth factors could be delivered as plasmid genes, not recombinant proteins which lead to *in situ* osteogenic protein production, thus inducing osteogenesis and bone repair. On the contrary, the critical factor in gene therapy includes the synthesis of clinically beneficial number of proteins around the defective osseous site in a sustained manner. Thus, major concern is the development of reliable gene delivery methods. Several practical factors also need to be considered, namely, age, gender, health of patients, and nature of the disease process for progressing a clinically applicable gene therapy for bone regeneration. Overall, a common platform for clinical experience, biological principles\' facts, demand, and commercial application is necessary for the technology development.
